Darron Locke, MD
General Practice · Roaring Spring, PANPI 1073507943
Payments from drug & device makers
Across 60 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$200
- Johnson & Johnson$132
- GSK$97
- Pfizer$91
- Abbott$53
- Novartis$49
- plus $396 from 18 others
What the payments were for
- Food & beverage$1,018100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 9 | $200 |
| Johnson & Johnson | 9 | $132 |
| GSK | 6 | $97 |
| Pfizer | 6 | $91 |
| Abbott | 3 | $53 |
| Novartis | 3 | $49 |
| Lilly USA, LLC | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Lundbeck LLC | 1 | $23 |
| Merck | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| AstraZeneca | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Novo Nordisk | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Amgen | 1 | $13 |
| Inspire Medical Systems, Inc. | 1 | $13 |
| Bristol Myers Squibb | 1 | $12 |
How this compares
$1,018 in reported general payments places this provider in the 85th percentile of 3,208 general practice providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 453 | $191,961 |
| NuplazidPimavanserin Tartrate | 25 | $67,111 |
| XareltoRivaroxaban | 170 | $65,591 |
| JardianceEmpagliflozin | 131 | $55,478 |
| OzempicSemaglutide | 58 | $51,255 |
| CreonLipase/Protease/Amylase | 24 | $38,451 |
| TrulicityDulaglutide | 27 | $31,264 |
| MyrbetriqMirabegron | 86 | $27,041 |
| FarxigaDapagliflozin Propanediol | 50 | $23,958 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $22,583 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 65 | $19,777 |
| EntrestoSacubitril/Valsartan | 53 | $12,795 |
| Atorvastatin Calcium | 810 | $10,560 |
| PremarinEstrogens, Conjugated | 19 | $10,133 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $9,825 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $91 | $202,095472 claims |
| GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Anoro Ellipta, Shingrix | $97 | $65,903150 claims |
| Johnson & JohnsonXarelto | $132 | $65,591170 claims |
| Boehringer IngelheimJardiance, Tradjenta | $14 | $64,179162 claims |
| Novo NordiskOzempic | $14 | $51,25558 claims |
| AbbVieCreon, Namzaric | $200 | $45,90749 claims |
| Lilly USA, LLCTrulicity | $47 | $31,26427 claims |
| Astellas Pharma US IncMyrbetriq | $36 | $27,04186 claims |
| AstraZenecaFarxiga | $15 | $23,95850 claims |
| NovartisEntresto | $49 | $12,79553 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,208 general practice providers in Pennsylvania.
Other general practice in Roaring Spring
- Corey AnolikPhiladelphia$2.1M
- Richard NagelbergPlymouth Meeting$1.4M
- Alan AtlasPhiladelphia$486K
- Susan McMahonPittsburgh$364K
- Yooson KimMorgantown$316K
- Carl MedgausMonroeville$192K
- Michele ColumboBryn Mawr$126K
- Michael WollockArdmore$113K
- Barry BartusiakWashington$104K
- Marc ManosPhiladelphia$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.